

Supplementary Table 3. Correlations between fecal calprotectin with sociodemographic, clinical features and disease severity in patients with MSA

MSA (<i>n</i> = 38)	<i>r_s</i>	<i>p</i> -value
Age	0.113	0.498
Sex	0.184	0.269
Smoking status	0.192	0.256
Body mass index	-0.198	0.247
Constipation severity		
Constipation severity score (PAC-SYM) (0–36)	-0.100	0.556
Less than 3 bowel movements per week	0.104	0.532
Disease duration	0.116	0.502
Age of onset	0.178	0.299
LEDD	-0.055	0.744
MSA severity (UMSARS parts I and II)	0.113	0.506
Cognitive function (MoCA)	-0.271	0.223

Spearman's rank correlation coefficient, denoted as *r_s* in the table. MSA, multiple system atrophy; LEDD, levodopa equivalent daily dose; PAC-SYM, Patient Assessment of Constipation Symptoms; UMSARS, Unified Multiple System Atrophy Rating Scale; MoCA, Montreal Cognitive Assessment.